#United States #Palo Alto #Surf Bio #Doug Hecker #SnapShot

Surf Bio Appoints Doug Hecker as Head of Technical Operations

In a strategic move to boost its operational capabilities, Surf Bio, a pioneering biopharmaceutical company, has recently appointed Doug Hecker as the Head of Technical Operations. This announcement marks a significant step in the company’s mission to innovate the way antibodies and biologics are delivered. Hecker’s extensive experience, spanning more than three decades, positions him ideally to propel Surf Bio to new heights in the industry.

A Seasoned Expert Joins the Team

Doug Hecker is well-regarded in the biopharmaceutical community, particularly for his profound knowledge in chemistry, manufacturing, and controls (CMC). Throughout his career, he has played pivotal roles in the development and commercialization of innovative excipients and drug products. He has a solid reputation for overseeing large-scale drug manufacturing and ensuring compliance with good manufacturing practices (GMP).

Before joining Surf Bio, Hecker significantly contributed to the launch of Captisol®, a novel excipient that revolutionized drug formulations and became integral to various pharmaceutical applications. He also spearheaded growth strategies at Hovione, a company recognized globally for its advancements in pharmaceutical spray drying technology. Most recently, he was the Vice President of Drug Delivery Technologies at Davos Pharma, where he led comprehensive technical development and commercialization strategies.

Accelerating Drug Delivery Innovations

Surf Bio’s SnapShot™ technology platform is poised to transform biologic drug delivery, allowing for high-dose biologics to be administered through a single autoinjector shot. Hecker’s appointment comes at a time when there is an increasing demand for convenient and effective drug delivery solutions. His leadership will be critical in scaling the SnapShot platform and accelerating clinical studies, enabling Surf Bio to forge deeper collaborations with major biopharmaceutical entities.

Bryan Mazlish, the CEO of Surf Bio, expressed enthusiasm about the hiring, stating, “Doug’s expertise in excipient development, spray drying, and large-scale drug product manufacturing makes him an invaluable addition to the Surf Bio team. His leadership will be instrumental in scaling the SnapShot platform and accelerating our path to clinical studies.”

Meeting the Market's Urgent Needs

With the rapid advancement of biologic therapies, the need for scalable delivery solutions has never been more pressing. Doug Hecker articulated his excitement about joining Surf Bio during a pivotal time for the biopharmaceutical industry. “The rapid growth of biologics is creating an urgent need for scalable, high-dose, subcutaneous delivery solutions,” Hecker noted. His insights into cGMP manufacturing and FDA regulatory compliance will be vital as Surf Bio strives to bring high-dose subcutaneous formulations to market quickly and efficiently.

About Surf Bio

Surf Bio is dedicated to revolutionizing the delivery of biologics and antibodies through its SnapShot™ platform, developed from pioneering research conducted at Stanford University’s Appel lab. The technology promises to change patient care by enabling the development of ultra-high concentration formulations of monoclonal antibodies (mAbs). With demonstrated efficacy and safety data, the SnapShot technology aims not only to improve patient outcomes but also to streamline the administration process for healthcare providers.

For more information about Surf Bio and its innovative approaches to drug delivery, visit www.surf.bio.